Charles River Laboratories CRL EBITDA

EBITDA at other companies

Labcorp HoldingsLH

$554.1M+12.4%

Rapid Micro BiosystemsRPID

-$13.15M-21.6%

Ginkgo BioworksDNA

-$46.23M-7.7%

Fortrea Holdings Inc.FTRE

$34.4M+111%

RevvityRVTY

$180.94M+6.7%

IQVIAIQV

$798M+2.0%

FAQ

What is Charles River Laboratories's EBITDA?

Charles River Laboratories (CRL) reported EBITDA of $187.18M in Q2 2026.

How has Charles River Laboratories's EBITDA changed year-over-year?

Charles River Laboratories's EBITDA decreased by 14.8% year-over-year, from $219.64M to $187.18M.

What is the long-term trend for Charles River Laboratories's EBITDA?

Over 4 years (2021 to 2025), Charles River Laboratories's EBITDA has grown at a -4.5% compound annual growth rate (CAGR), from $855.4M to $710.81M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.